The involvement of anti-beta 2GPI/HLA-DR antibodies (neoself antibodies) in infertility

aβ2GPI/HLA-DR is involved in the pathophysiology of recurrent pregnancy loss. This study aimed to evaluate aβ2GPI/HLA-DR in infertility. This prospective cohort study was approved by IRB, and written informed consent was obtained from participants. We measured serum levels of aβ2GPI/HLA-DR (normal <73.3U) in 224 infertile women, and compared patient backgrounds and the results of assisted reproductive technology (ART) between women with (A; N=40) and without aβ2GPI/HLA-DR (B; N=184). Recurrent implantation failure (RIF) was defined as three or more implantation failures following in vitro fertilization and embryo transfers. Of the 224 patients, 17.9% (40) tested positive. The prevalence of RIF and endometriosis was higher in group A compared with B (RIF; A vs B: 43.5%, 10/23 vs 20.8%, 26/125; P = 0.031, endometriosis; 34.2%, 13/40 vs 17.9%, 32/184; P = 0.039). Logistic regression analyses revealed that endometriosis was selected as risk for antibody’s positivity in infertile patients ([OR] 2.60, 95% CI 1.13–5.96; P = 0.024), and that RIF was found to be a risk factor for antibody positivity’s in ART patients (OR 3.55, 95% CI 1.30–9.93; P = 0.014). The pregnancy rate among group A who received low dose aspirin (LDA) from embryo transfer was 47.4% (10/19), tended to be higher than 21.1% (4/19) in the patients that did not receive LDA (P= 0.09), and live birth rates was 36.8% (7/19), significantly higher than 5.3% (1/19) in non-LDA group (P= 0.04). aβ2GPI/HLA-DR. may be associated with the pathophysiology of infertility, especially with endometriosis and RIF.